TScan Therapeutics, Inc.
TCRX
$1.53
$0.096.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -82.58% | -29.96% | -31.67% | -33.59% | -4.75% |
| Total Depreciation and Amortization | -44.45% | -20.14% | -13.89% | -16.34% | -13.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 217.25% | -8.13% | 48.61% | 27.11% | -49.44% |
| Change in Net Operating Assets | 184.85% | -100.98% | 407.03% | 45.70% | -2,082.39% |
| Cash from Operations | -15.34% | -448.24% | -19.09% | -24.08% | -48.44% |
| Capital Expenditure | -89.34% | 3.45% | -105.24% | 15.87% | 65.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,083.08% | -34.98% | -- | -- | -- |
| Cash from Investing | 1,326.71% | -34.09% | -7,927.62% | 4,415.39% | 238.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,889.47% | -- | -23.03% | -- | -90.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 38.83% | -- | 100.00% |
| Cash from Financing | 240,373.68% | 588.10% | 19.10% | -- | -82.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 308.72% | -103.25% | -10.23% | 129.29% | -26.36% |